Want to join the conversation?
For 2Q16, $EFX expects revenue, including Veda, to be $795-805MM. Adjusted EPS is expected to be $1.34-1.36, up 17-18% versus 2Q15. For 2016, $EFX expects revenue, including Veda, to be $3.05-3.15Bil versus previous guidance of $3.0-3.1Bil. Adjusted EPS for 2016 is expected to be $5.15-5.25, up 14-17% versus previously guided $4.95-5.05.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)